Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma.
Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma.
复制标题
DOI：
10.3390/diagnostics11081340
复制
发表时间：
2021-07-26
期刊：
影响因子：
--
通讯作者：
Shih TT
中科院分区：
文献类型：
--
作者：
Chen BB;Shao YY;Lin ZZ;Hsu CH;Cheng AL;Hsu C;Liang PC;Shih TT
目的：本研究评估了动态对比增强（DCE）-MRI和体素内非相干运动弥散加权成像（IVIM DWI）参数，以前瞻性预测接受来那度胺（一种双重抗血管生成和免疫调节剂）作为II期临床试验二线治疗的晚期肝细胞癌（HCC）受试者的生存结局。材料与方法：前瞻性入组了44例接受索拉非尼一线治疗后进展的晚期HCC患者。治疗前MRI参数-从DCE-MRI（峰值、斜率、AUC、Ktranss、Kep和Ve）、表观扩散系数（ADC）和IVIM DWI（纯扩散系数（D）、假扩散系数（D*）和灌注分数（f））获得-来自最大的肝肿瘤。采用考克斯模型分析各参数与无进展生存期（PFS）和总生存期（OS）的关系。结果：中位PFS和OS分别为2.3和8.0个月。单变量分析表明，具有高斜率的参与者（p = 0.024），Kep（p < 0.001），ADC（p = 0.018）数值较低值者PFS较长;肿瘤尺寸小（p = 0.006）、斜率高（p = 0.01）、ADC值高（p = 0.015）和f值高（p = 0.012）的受试者的OS比肿瘤尺寸小（p = 0.006）、斜率高（p = 0.01）、ADC值高（p = 0.015）和f值低（p = 0.012）的受试者的OS长。考克斯多变量分析显示，Kep（p < 0.001）和ADC（p = 0.009）仍然是PFS的独立预测因子;斜率（p = 0.003）和ADC（p = 0.009）仍然是OS的独立预测因子。此外，在进行Bonferroni校正后，Kep和斜率仍然具有显著性（p < 0.005）。结论：治疗前DCE-MRI和IVIM DWI参数，尤其是斜率和ADC，可以预测接受来那度胺作为二线治疗的HCC受试者的PFS和OS。
Objective: This study assessed dynamic contrast-enhanced (DCE)-MRI and intravoxel incoherent motion diffusion-weighted imaging (IVIM DWI) parameters to prospectively predict survival outcomes in participants with advanced hepatocellular carcinoma (HCC) who received lenalidomide, a dual antiangiogenic and immunomodulatory agent, as second-line therapy in a Phase II clinical trial. Materials and methods: Forty-four participants with advanced HCC who had progression after sorafenib as first-line treatment were prospectively enrolled. Pretreatment MRI parameters—obtained from DCE-MRI (peak, slope, AUC, Ktrans, Kep, and Ve), apparent diffusion coefficient (ADC), and IVIM DWI (pure diffusion coefficient (D), pseudodiffusion coefficient (D*), and perfusion fraction (f))—were derived from the largest hepatic tumor. The Cox model was used to investigate the associations of the parameters with progression-free survival (PFS) and overall survival (OS). Results: Median PFS and OS were 2.3 and 8.0 months, respectively. Univariate analysis showed that participants with a high slope (p = 0.024), Kep (p < 0.001), and ADC (p = 0.018) values had longer PFS than those with low values; participants with a small tumor size (p = 0.006), high slope (p = 0.01), ADC (p = 0.015), and f (p = 0.012) values had longer OS than those with low values did. Cox multivariable analysis revealed that Kep (p < 0.001) and ADC (p = 0.009) remained independent predictors of PFS; slope (p = 0.003) and ADC (p = 0.009) remained independent predictors of OS. Moreover, Kep and slope were still significant after Bonferroni correction was performed (p < 0.005). Conclusion: Both pretreatment DCE-MRI and IVIM DWI parameters, especially slope and ADC, may predict PFS and OS in participants with HCC receiving lenalidomide as second-line therapy.
登录
查看更多内容
影响因子：
2
作者：
Kakite S;Dyvorne HA;Lee KM;Jajamovich GH;Knight-Greenfield A;Taouli B
通讯作者：
Taouli B
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
5.9
作者：
Wu, Li-Fang;Rao, Sheng-Xiang;Zeng, Meng-Su
通讯作者：
Zeng, Meng-Su
影响因子：
25.7
作者：
Hsu, Chiun;Yang, Tsai-Sheng;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii
影响因子：
25.7
作者：
Hsu, Chao-Yu;Shen, Ying-Chun;Shih, Tiffany Ting-Fang
通讯作者：
Shih, Tiffany Ting-Fang